ClinicalTrials.gg
RecruitingNCT05303467FRONTIERUpdated Oct 30, 2026

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

A Phase 1 interventional study of TheraSphere GBM in Glioblastoma Multiforme and Recurrent Glioblastoma, sponsored by Boston Scientific Corporation. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Boston Scientific Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.
Updated Sep 28, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
532nd of 1,155
36 · median 33
Started
2022
with 56 others
Phase 1
481 of 1,302
70 open now
Primary completion
2027-01
later than 112 of 321 live
Registered
1,085th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 532nd largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 57 that started in 2022, is one of 481 in phase 1, reaches primary completion later than 112 of the 321 other live ones, and was the 1,085th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

Read the detailed description

Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in \<7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.

The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.

In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.

03

Conditions studied

  • Glioblastoma Multiforme
  • Recurrent Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 years or older and has signed and dated the trial form (ICF)
  2. ≥ 12 weeks
  3. Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule
  4. History of a confirmed diagnosis of glioblastoma per 2021 WHO criteria
  5. Have radiographic evidence of tumor progression/recurrence with (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria
  6. Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
  7. Prior cranial radiation dose \< 66 Gy
  8. ≤ 2
  9. The interval since completion of cranial radiotherapy must be > 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks
  10. Interval since last systemic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.

    1. ≥ 4 weeks since last dose of temozolomide
    2. ≥ 6 weeks since last dose of lomustine or other nitrosourea
    3. ≥ 2 weeks since last dose of a small molecule targeted agent (Tyrosine Kinase Inhibitor or similar)
    4. ≥ 6 weeks from last dose of last intravenous bevacizumab infusion, or other antibody-based VEGF therapy
  11. If receiving , patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration
  12. Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:

    1. ≤ 1.2 (in absence of anticoagulation)
    2. ≥ 100,000/L
    3. Creatinine ≤1.5 mg/dL
    4. ≥1.5 x 10\^9/L
    5. ≥9.0 g/dL
  13. Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of )
  14. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of as confirmed by the investigator
  15. Angiographic Mapping Inclusion Criteria:

    1. Accessible neurovascular anatomy that allows for safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all of the T1 enhancing component of target lesion confirmed by neuro-interventional team.
    2. Total treatment volume is ≤ 150cc as determined by multidisciplinary team.
  16. Additional Inclusion Criteria:

    1. Group A: perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain
    2. Group B: perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain
    3. Group C: perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain
    4. Group D: perfused volume encompasses the dominant hemisphere and eloquent regions of the brain

Exclusion criteria

Exclusion Criteria:

  1. Have bilateral gadolinium enhancing disease, tumor located in the posterior fossa, tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle), tumor approximating or invading the brainstem and/or optic chiasma, , or extracranial disease
  2. Have received more than 1 course of prior cranial radiotherapy (EBRT)
  3. Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy
  4. Have received more than 2 systemic treatment protocols (), not including maintenance temozolomide
  5. Have received prior intra-arterial cerebral infusion therapy
  6. Have received more than 2 surgical GBM-related procedures
  7. Have received prior thoracic radiation therapy
  8. Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)
  9. Have uncontrolled epilepsy
  10. Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:

    1. Hypertension grade 3 or higher without adequate control on medications
    2. Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg)
    3. Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of \< 60 mmHg, or oxygen saturation (Sa,O2) of \< 90%) as measured by fingertip pulse oximeter
    4. Ongoing or active bacterial or viral infection requiring systemic treatment (including )
    5. Pneumonitis
    6. Psychiatric illness/social situations that would limit compliance with study requirements
    7. Peripheral Neuropathy ≥ grade 1
    8. Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
  11. Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)
  12. Patients with a history of an active other within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma
  13. Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation
  14. Medical to undergo contrast-enhanced magnetic resonance imaging (MRI)
  15. Known history of reactions to iodinated and/or gadolinium-based contrast
  16. Subject has received any other agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
  17. Angiographic Mapping Exclusion Criteria: Patients with significant vascular disease, significant AV shunting, or anatomic tortuosity on MR/CT Angiogram precluding safe or feasible vascular access
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Treatment Group A

    Subjects in which the perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

    Device: TheraSphere GBM

  • Experimental
    Treatment Group B

    Subjects in which the perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

    Device: TheraSphere GBM

  • Experimental
    Treatment Group C

    Subjects in which the perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

    Device: TheraSphere GBM

  • Experimental
    Treatment Group D

    Subjects in which the perfused volume encompasses the dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

    Device: TheraSphere GBM

Interventions

  • DeviceTheraSphere GBM

    Single treatment of TheraSphere GBM device

    Also known as: TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)

06

What researchers measure

Primary outcomes

  1. The number of grade 3-5 non-hematological toxicities

    Time frame: 30 days post index procedure

  2. The number of ≥ grade 3 CNS toxicities related to non-target embolization

    Time frame: 30 days post index procedure

  3. Occurrence of symptomatic brain radiation necrosis requiring medical or surgical intervention and confirmed by pathology

    Time frame: 30 days post index procedure

  4. The number of Grade 4 neutropenia events persisting for longer than 5 days

    Time frame: 30 days post index procedure

  5. The number of grade 4 febrile neutropenia

    Time frame: 30 days post index procedure

  6. The number of grade 4 thrombocytopenia or grade 3 thrombocytopenia with hemorrhage

    Time frame: 30 days post index procedure

Secondary outcomes

  1. Rate of any treatment-related adverse events and treatment-related serious adverse events (not including predefined Limiting Toxicities) from first patient enrolled through study completion.

    Time frame: Enrollment through 6 months post index procedure

  2. Change in post-treatment neurological function as assessed by the National Institute of Health Stroke Scale (NIHSS).

    The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

    Time frame: Enrollment through 6 months post index procedure

  3. Change in post-treatment neurological function as assessed by the modified Rankin Scale (mRS).

    The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability on a scale from 0 (no symptoms at all) to 6 (death).

    Time frame: Enrollment through 6 months post index procedure

  4. Technical Success/Feasibility of TheraSphere GBM - ability to deliver the projected radiation absorbed dose (+/- 20%) to the perfused volume for all patients treated with the device. Assessed from pre-screening through post-device delivery PET-CT/MRI.

    Time frame: Pre-screening through post-device delivery PET-CT/MRI.

  5. Objective Response Rate* (ORR) from first patient enrolled through study completion

    Time frame: Enrollment through 6 months post index procedure

  6. Progression Free Survival* (PFS) from first patient enrolled through study completion

    Time frame: Enrollment through 6 months post index procedure

  7. Overall Survival (OS) from first patient enrolled through study completion

    Time frame: Enrollment through 6 months post index procedure

07

Study locations

7 of 9 sites recruiting
08

References and documents

Publications

  • Meiselman S, Thomas MA, Giardina JD, Zheleznyak A, Thorek DLJ, Malone CD. Advances in Radioembolization for Liver Cancer. J Vasc Interv Radiol. 2025 Dec;36(12):1876-1881. doi: 10.1016/j.jvir.2025.07.018. PubMed 41276366 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2027, 54 months after the start.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 54 months is above that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Oct 2026 → Jan 2027 and completion Apr 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 31, 2022
StartActual
Jul 30, 2022
Primary completionEst.
Jan 31, 2027was Oct 2026
CompletionEst.
Jun 30, 2027was Apr 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
University of California San Diego is now Recruiting
Sep 28, 2026
Primary completion
Oct 31, 2026→Jan 31, 2027
Sep 28, 2026
Study completion
Apr 30, 2027→Jun 30, 2027
Sep 28, 2026
Show all 2 updates
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    University of California San Diego is now Recruiting
    Primary completion Oct 31, 2026→Jan 31, 2027
    Study completion Apr 30, 2027→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05303467
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Jul 30, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Sally Linda
Contact
Sally.Linda@bsci.com
952-201-3102
Lilian Liu Pan
Contact
Lilian.LiuPan@bsci.com
858-888-5682
Riad Salem, M.D.
principal investigator · Northwestern University
Roger Stupp, M.D.
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion